Aspen Pharmacare Holdings Ltd's Subsidiary Announces Acquisition Of GlaxoSmithKline Plc's Arixtra And Fraxiparine/Fraxodi Brands

Monday, 30 Sep 2013 07:03am EDT 

Aspen Pharmacare Holdings Ltd (Aspen) announced that Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen, will acquire from GlaxoSmithKline Plc (GSK )the Arixtra and Fraxiparine/Fraxodi brands (the Brands) and business worldwide, except in China, Pakistan and India (the Excluded Territories) and Aspen will acquire from GSK a sterile production site which manufactures the Brands at Notre Dame de Bondeville, France (he Site), collectively (the Proposed Transaction). The aggregate purchase consideration payable by Aspen in respect of the Proposed Transaction is GBP600 million (equivalent to R9 798 million); being the sum of the value of the Business of GBP504.7 million (equivalent to R8 242 million) and the value of the Manufacturing Business being GBP95.3 million (equivalent to R1 556 million), plus the value of the Manufacturing Inventory and Manufacturing Stocks, expected to be of the order of GBP100 million (equivalent to R1 633 million). The Purchase Consideration will be settled in cash. 

Company Quote

0.12 +0.28%
2 Jul 2015